Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

2328 - Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a Phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb

Date

11 Sep 2017

Session

Immunotherapy of cancer

Presenters

Omid Hamid

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

O. Hamid1, W. Ros2, J.A. Thompson3, S. Hu-Lieskovan4, F.A.L.M. Eskens5, A. Diab6, T. Doi7, J. Wasser8, J. Spano9, N. Rizvi10, E. Angevin11, A. Chiappori12, P.A. Ott13, B.J. Ganguly14, C. Fleener15, V. Dell16, K. Liao16, T. Joh16, J. Chou17, A. El-Khoueiry18

Author affiliations

  • 1 Medicine, The Angeles Clinic and Research Institute, 90025 - Los Angeles/US
  • 2 Netherlands Cancer Institute, Netherlands Cancer Institute, Amesterdam/NL
  • 3 Department Of Medicine, University of Washington Seattle Cancer Care Alliance, 98109 - Seattle/US
  • 4 Medicine, UCLA - School of Medicine, 90095 - Los Angeles/US
  • 5 Department Of Medical Oncology, Erasmus MC Cancer Institute, 3015 CE - Rotterdam/NL
  • 6 Department Of Melanoma Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 7 Medical Oncology, National Cancer Center Hospital East, Chiba/JP
  • 8 Division Of Hematology And Medical Oncology, UConn Health, Neag Comprehensive Cancer Center, Farmington/US
  • 9 Medical Oncology, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 10 Medicine, Columbia University, New York, NY/US
  • 11 Medicine, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 12 Medicine, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 13 Medicine, Dana-Farber Cancer Institute, 2215 - Boston/US
  • 14 Early Oncology Development And Clinical Research, Pfizer Inc, South San Francisco/US
  • 15 Early Oncology Development And Clinical Research, Pfizer Inc, Groton/US
  • 16 Early Oncology Development And Clinical Research, Pfizer Inc, La Jolla/US
  • 17 Research And Development, Pfizer, 94080 - South San Francisco/US
  • 18 Medicine, University of Southern California, Los Angeles/US
More

Resources

Abstract 2328

Background

PF-8600 and utomilumab are fully human IgG2 agonistic monoclonal antibodies directed at tumor necrosis factor receptor superfamily receptors OX40 and 4-1BB, respectively. In general, OX40 has a greater impact on CD4 T cell function, while 4-1BB has more impact on CD8 T cell function. Dual targeting of OX40 and 4-1BB synergistically induced CD8 and cytotoxic CD4 T cell clonal expansion in pre-clinical models. A Phase I study (NCT02315066), evaluated PF-8600 alone and in combination with utomilumab. As seen previously for utomilumab alone, PF-8600 monotherapy was tolerable at all dose levels, providing rationale to combine PF-8600 with utomilumab.

Methods

Non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, bladder, gastric or cervical cancer patients (pts) unresponsive to available therapies or where no standard therapy is available are treated with PF-8600 at dose levels 0.1 mg/kg to 3 mg/kg q2w in combination with utomilumab at either 20 mg or 100 mg q4w intravenously. Blood was collected for PK/PD analysis.

Results

At time of data cut-off on 30-Jan 2017 (study ongoing), 28 pts had enrolled in 4/5 planned dose cohorts. No drug-related deaths, dose-limiting toxicities, or suspected unexpected serious adverse reactions have been confirmed to date. All drug-related adverse events (AEs) were grade (G) 1-2. The most common were nausea (10.7%), decreased appetite (7.1%) and fatigue (7.1%). Nine (32.1%) G3, 3 (10.7%) G4 and 2 (7.1%) G5 all-causality AEs were reported (G5 AEs in lowest dose cohort). Combination treatment resulted in greater increases in expression of activation and proliferation markers on CD8 memory T cells, in particular, and memory T cell subsets overall, than PF-8600 alone. Preliminary PK and efficacy data will be shown.

Conclusions

To date, dose escalation combining active monotherapy doses of PF-8600 and utomilumab has not demonstrated toxicity beyond that expected from either alone. Safety, efficacy, PK, and PD data from dose escalation will aid selection of optimal biologic doses for further evaluation and expansion.

Clinical trial identification

NCT02315066

Legal entity responsible for the study

Pfizer Inc

Funding

Pfizer Inc

Disclosure

O. Hamid: Consulting/Advising: Amgen, Novartis, Roche, Bristol-Myers Squibb, Merck; Speakers\' Bureau Bristol-Myers Squibb, GNE, Novartis, Amgen; Research Funding (Institution): AstraZeneca, Bristol-Myers Squibb, Celldex, GNE, Immunocore, Incyte, Merck, Merck Serono, MedImmune, Novartis, Pfizer, Rinat, Roche. J.A. Thompson: Honoraria: Celledex Consulting or advisory role: Celledex Research Funding (to institution): Bristol-Myers Squibb Agensys Seattle Genetics Pfizer Trillium Therapeutics Merck Inc. S. Hu-Lieskovan: Consulting: Amgen, Merck, Novartis, Vaccinex, Emergent BioSolutions Contracted Research: Pfizer, Plexxikon, Genentech, Neon Research Support: Bristol-Myers Squibb, Merck Travel Support: Amgen, Merck, Novartis, Vaccinex, Emergent BioSolutions, Neon. F.A.L.M. Eskens: Consulting or Advisory Role: Daiichi Sankyo Ipsen Pfizer Merck Inc. Novartis Pharma KK Travel, Accommodations, Expenses Daiichi Sankyo Ipsen Roche-Peru. A. Diab: Consulting/advisory: Nektar, CureVac, Celgene Travel/accomodations/expenses: Nektar Research funding (to institution): Nektar, Idera, Celgene, Pfizer. T. Doi: Advisory: Lilly, Chugai, Kyowa Hakko Kirin, Nippon BI, Novartis, MSD, Daiichi Sankyo, Amgen Funding to institution: Taiho, Novartis, Merck Serono, Astellas, MSD, Janssen, BI, Takeda, Pfizer, Lilly, Sumitomo, Chugai, Bayer, Kyowa, Daiichi Sankyo, Celgene. J. Wasser: Have received research support from Pfizer by means of a material transfer agreement. J-P. Spano: Adboard with Pfizer (Breast cancer). N.A. Rizvi: Advisory Board: Merck, AstraZeneca, Roche, Bristol-Myers Squibb, Novartis, Pfizer, Lilly, Novartis, Abbvie Co-founder and shareholder: Gritstone Oncology Scientific Advisory Board: Nilogen Oncosystems. A. Chiappori: Participated in advisory boards for Genentech, Novartis, Bristol-Myers Squibb, ARIAD and have also received honoraria from Genentech, Merck, Celgene, Boehringer Ingelheim. Received honoraria from Pfizer too, but not within the last year. P.A. Ott: Grants to the institution and personal fees from Bristol-Myers Squibb, CytomX, Celldex, Pfizer and Merck, personal fees from Neon Therapeutics, Amgen, Novartis, and Roche/Genentech, and grants from AstraZeneca/MedImmune, outside of the submitted work. B.J. Ganguly, K. Liao, T. Joh, J. Chou, C. Fleener: Employee and stockholder of Pfizer Inc. V. Dell: Contractor for Pfizer. A. El-Khoueiry: Advisory: CytomX, Bristol-Myers Squibb, AstraZeneca Speakers Bureau: Merrimack Honoraria: Merrimack, Bayer, Novartis, Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.